Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Alban Linnenbach is active.

Publication


Featured researches published by Alban Linnenbach.


Melanoma Research | 1997

Melanoma cell lines from different stages of progression and their biological and molecular analyses.

Kapaettu Satyamoorthy; Emma Dejesus; Alban Linnenbach; Barbara Kraj; Douglas L. Kornreich; Susan Rendle; David E. Elder; Meenhard Herlyn

The biological and molecular characteristics of cell lines from metastatic melanomas have been extensively studied but less is known about cells from the biologically earliest stage of primary melanoma. The overall success rate of establishing permanent cell lines from such lesions is only 10% of that for biologically late primary or metastatic melanomas, although our laboratory now has eight cell lines available. The cells are immortal but show reduced or no proliferation in soft agar and immunodeficient mice when compared with primary melanomas from the biologically advanced vertical growth phase. Metastatic melanoma cell lines from patients with familial melanoma or xeroderma pigmentosum are biologically similar to those from patients with spontaneous melanomas. Irrespective of the malignant stages, deletions and mutations can occur in exons 1–3 of the p16INK4A gene. DNA fingerprinting was then employed to demonstrate the uniqueness of individual cell lines and to confirm the identity of cell lines derived from same patients. These cell lines are an excellent resource to investigate melanoma progression.


Journal of Immunology | 2001

Isolation of the Melanoma-Associated Antigen p23 Using Antibody Phage Display

Jian Li; Sarita Pereira; Patricia Van Belle; Ping Tsui; David E. Elder; David W. Speicher; Keith Deen; Alban Linnenbach; Rajasekharan Somasundaram; Rolf Swoboda; Dorothee Herlyn

The general responsiveness of human melanoma to immunotherapy has been well established, but active immunotherapy of melanoma has been hampered by insufficient information on the immunogenicity of melanoma-associated Ags in patients. In this study, we isolated a recombinant phage-Fab clone (A10-5) from a phage-Fab library derived from the B cells of a melanoma patient in remission after immunotherapy. Purified A10-5 Fab bound at high levels to cultured melanoma cell lines and to tissue sections of metastatic and vertical growth phase primary melanoma, but not to radial growth phase primary melanoma, nevi, or normal skin. A10-5 Fab bound to both the surface and the cytoplasm of cultured melanoma cells, but only to the cytoplasm of cultured fibroblasts. Western blot analysis revealed A10-5 Fab reactivity with a 33- and a 23-kDa glycoprotein under nonreducing conditions, and with a 23-kDa protein only under reducing conditions. A cDNA with an open reading frame predicted to encode a 23-kDa protein was cloned by screening a melanoma cell cDNA library with A10-5 Fab. This protein (p23) is the human homologue of the murine tumor transplantation Ag P198 that interacts with the cytoplasmic domain of ErbB-3 expressed by melanoma cells. Thus, the Ab phage display method has identified a novel, stage-specific melanoma-associated Ag that may have therapeutic and diagnostic value.


Genomics | 1991

The exon-intron organization of the human erythrocyte α-spectrin gene

Leszek Kotula; Lisa D. Laury-Kleintop; Louise C. Showe; Kenneth Sahr; Alban Linnenbach; Bernard G. Forget; Peter J. Curtis

Abstract The human erythrocyte α-spectrin gene which spans 80 kbp has been cloned from human genomic DNA as overlaping λ recombinants. The exon-intron junctions were identified and the exons mapped. The gene is encoded by 52 exons whose sizes range from 684 bp to the smallest of 18 bp. The donor and acceptor splice site sequences match the splice site consensus sequences, with the exception of one splice site where a donor sequence begins with -GC. The size and location of exons do not correlate with the 106-amino-acid repeat, except in three locations where the surrounding codons are conserved as well. The lack of correspondence between exons and the 106-amino-acid repeat is interpreted to reflect the appearance of a spectrin-like gene from a minigene early in the evolution of eukaryotes. Since current evidence indicates that introns were present in genes before the divergence of prokaryotes and eukaryotes, it is possible that the original distribution of introns within the minigene has been lost by the random deletion of introns from the spectrin gene.


Journal of Immunological Methods | 1992

Molecular cloning of murine monoclonal anti-idiotypic Fab

Yasushi Kasai; Dorothee Herlyn; Melinda Sperlagh; Haruhiko Maruyama; Shuzo Matsushita; Alban Linnenbach

Anti-idiotypic antibodies (Ab2) binding to idiotopes on antibodies with various antigen binding specificities (Ab1) are potential regulators of immunity in a variety of diseases, such as autoimmunity, cancer, and viral, bacterial, or parasitic infections. Furthermore, Ab2 are useful probes for the characterization of receptor/ligand interactions. Thus far, Ab2 production has been limited to the isolation of polyclonal Ab2 from immune sera or monoclonal Ab2 from hybridoma supernatants. However, both approaches have produced a limited number of Ab2. As an alternative approach, we demonstrate here the production of Ab2-Fab by using repertoire cloning. Using HIV-1 as a model system, the Ab2-Fab were generated from the spleens of mice immunized with the virus-neutralizing and syncytia-inhibiting anti-HIV-1 monoclonal antibody 0.5 beta. A bacteriophage lambda vector system was used to express a combinatorial library in Escherichia coli. Iodinated 0.5 beta was used to identify 17 Ab2-Fab clones. DNA sequence analysis of five clones revealed three similar kappa and Fd combinations. The Ab2-Fab bound with high affinity (3.5-6.5 x 10(9) liters/mol) specifically to the Ab1 and not to isotype-matched antibodies with unrelated specificities. The three Ab2-Fab probably bind to the same idiotope on the Ab1 as demonstrated in cross-competition binding studies. The Ab2-Fab inhibited binding of the Ab1 to antigen, and therefore, may functionally mimic the epitope defined by the Ab1. Repertoire cloning of Ab2-Fab may facilitate the generation of Ab2 that have potential as modulators of immune responses against various antigens.


International Reviews of Immunology | 1991

Epitope- and Antigen-specific Cancer Vaccines

Dorothee Herlyn; Alban Linnenbach; Hilary Koprowski; Meenhard Herlyn

Anti-idiotypic antibodies (Ab2) that functionally mimic epitopes associated with human cancer cells are the most specific cancer vaccines currently available. Ab2 can induce specific humoral anti-tumor immunity in cancer patients. However, the potential of Ab2 for inducing cellular immunity in cancer patients still requires demonstration. Clonotypic antibodies directed against the combining site for tumor Ag on human T-cell clones may provide highly effective reagents for inducing protective T-cell immunity against human cancer. A new generation of cancer vaccines, molecularly cloned tumor-associated antigens (Ag), has recently been developed. Recombinant Ag have been successfully expressed in vectors allowing large scale production of Ag for immunization of cancer patients. Recombinant tumor Ag was shown to induce specific and protective immunity in experimental animals. In contrast to Ab2, which may mimic a single cancer-associated epitope, recombinant Ag express multiple epitopes that are potentially immunogenic. Ag vaccines, therefore, may be more effective in arresting tumor growth than single epitope (Ab2) vaccines because tumor destruction by antibodies is dependent on antibody density on tumor cell surfaces. In light of the important roles that both B and T cells play in the control of tumor growth, the demonstration of induction of specific B and T cell-immunity by recombinant tumor Ag and Ab2 in experimental animals is encouraging. Ultimately, the immunomodulatory role of both types of vaccines has to be compared in cancer patients who are immunologically tolerant to many Ag/epitopes expressed by their growing tumors. The development of both Ab2 and recombinant Ag for single antigenic systems provides the first step towards this goal.


Journal of Immunological Methods | 1989

Rapid and sensitive method to detect expression of growth factor receptors

Ewa M. Rakowicz-Szulczynska; Alban Linnenbach; Hilary Koprowski

A sensitive method to analyze growth factor receptor expression is described that is based on precipitation of the receptor by the growth factor. The precipitate that forms after incubation of pure, membrane-free cytoplasm with the growth factor contains both the receptor and the corresponding mRNA. With this method, nerve growth factor (NGF), epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) receptors were detected in several tumor cell lines thought previously to be receptor-negative. This method is more sensitive than existing cell surface approaches, permitting the detection of growth factor receptor synthesis even in the absence of detectable cell surface expression. The method is comparable in sensitivity to Northern blot hybridization but does not require DNA probes.


Journal of Immunology | 2003

Recombinant CD63/ME491/Neuroglandular/NKI/C-3 Antigen Inhibits Growth of Established Tumors in Transgenic Mice

Jian Li; Weiping Li; Shaohong Liang; Dewei Cai; Marie Paule Kieny; Lutz Jacob; Alban Linnenbach; Jan W. Abramczuk; Hans Bender; Katrin Sproesser; Rolf Swoboda; Rajasekharan Somasundaram; DuPont Guerry; Dorothee Herlyn

Attempts to vaccinate against tumors can be hindered by the induction of immunological tolerance to the target Ag as a result of Ag expression on normal tissues. In this study, we find that transgenic mice expressing the melanoma-associated Ag CD63/ME491/neuroglandular/NKI/C-3 on their normal tissues do, in fact, exhibit immunological tolerance to the Ag, recapitulating the conditions in cancer patients. In these mice, growth of murine melanoma cells expressing the Ag after gene transfer was inhibited by immunization with Ag-expressing recombinant vaccinia virus combined with IL-2, but not by immunization with the protein alone, anti-idiotypic Abs, or irradiated tumor cells. The effect of the recombinant virus was demonstrated both for nonestablished and established tumors. Infiltration with both CD4+ and CD8+ T lymphocytes was significantly more extensive in tumors from experimental mice than in tumors from control mice. MHC class I-positive, but not class I-negative, tumors were inhibited by the vaccine, suggesting that MHC class I-restricted T lymphocytes play a role in the antitumor effects. Abs did not appear to be involved in the vaccine effects. CD63 was immunogenic in 2 of 13 melanoma patients, pointing to the potential of this Ag, combined with IL-2, as a vaccine for melanoma patients.


Human Genetics | 1995

Three new dinucleotide repeat polymorphisms on human chromosome 9: D9S970, D9S971, and D9S972

Barry S. Kimmel; Pierre Miniou; Shira L. Robbins; S. Bruce Malkowicz; Alban Linnenbach

Three human chromosome 9-specific cosmid recombinants containing (CA)n microsatellites are described. Threse microsatellite loci, D9S970, D9S971, and D9S972, were observed to have heterozygosities of 0.78, 0.84, and 0.82, respectively. Subchromosomal localizations were determined by R-banding and fluorescence in situ hybridization.


Archive | 1982

The Use of Mouse-Human and Human-Human Hybridomas in Human Genetics and Immunology

Carlo M. Croce; Alban Linnenbach; Thomas W. Dolby; Hilary Koprowski

In order to investigate the molecular basis of human immunodeficiencies and to understand the immunological basis of human autoimmune diseases, it is important to be able to clone the genes for human immunoglobulin chains and the autoantibodies responsible for the pathogenesis of the autoimmune diseases respectively.


Archive | 1982

Viral-DNA Vectors in the Analysis of Mammalian Differentiation

Alban Linnenbach; Carlo M. Croce

Advances in molecular biology and methods in mammalian cell culture have been utilized in the construction of DNA-transformed, pluripotent murine teratocarcinoma stem cells (Linnenbach et al., 1980) that have proven to be a useful in vitro model for the study of the regulation of gene expression during differentiation (Huebner et al., 1981; Croce et al., 1981; Linnenbach et al., 1981).

Collaboration


Dive into the Alban Linnenbach's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David E. Elder

Hospital of the University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

DuPont Guerry

University of Pennsylvania

View shared research outputs
Researchain Logo
Decentralizing Knowledge